# VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil

> **NCT00171015** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 212 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** valsartan plus hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00171015
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171015, "VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00171015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*